XHE - SPDR S&P Health Care Equipment ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
+0.07 (+0.12%)
As of 12:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close62.67
Bid62.70 x 1200
Ask62.77 x 900
Day's Range62.56 - 62.81
52 Week Range46.31 - 64.69
Avg. Volume13,184
Net Assets153.58M
PE Ratio (TTM)N/A
YTD Return26.28%
Beta (3y)0.79
Expense Ratio (net)0.35%
Inception Date2011-01-26
Trade prices are not sourced from all markets
  • Why a $475,000 drug price tag isn't expensive
    Yahoo Finance Video2 months ago

    Why a $475,000 drug price tag isn't expensive

    Novartis got government approval for a new cancer therapy. The treatment will cost a staggering $475,000, and it will help children and young adults with a certain type of Leukemia. Yahoo Finance's Seana Smith, Nicole Smith and Rick Newman react to what Wall Street is saying about the drug.

  • Benzinga13 days ago

    This Healthcare ETF Continues Beating Higher

    The healthcare sector is the second-best performer in the S&P 500 this year behind technology. Traditional, diversified healthcare exchange traded funds are delivering for investors. Just look at the Health ...

  • Barrons.com21 days ago

    Two Healthcare Tools & Diagnostics Stock Bargains Amid The Industry's Full Valuations

    Goldman Sachs' Patrick Donnelly and Charles Steinman assumed coverage of the life science tools and diagnostics sector with a Neutral rating today: While the believe that strong end markets provide one of the best, sustainable growth profiles in healthcare, that fact is already reflected in valuations. Donnelly and Steinman write that the end markets for this sector, including biopharma, academic/government, industrial/applied, and clinical, will stay healthy, which translates into organic growth of 4% to 5%, for the tools and diagnostics industries--although that is down slightly from recent 5% to 6% growth.  The main driver of this is their anlaysis that shows biopharma market will decelerate to mid-single digit growth, on slowing R&D spending, along with risk from M&A and drug pricing legislation.

  • Barrons.comlast month

    Who Will Win A $6 Billion Lung Caner Biopsy Opportunity?

    Among cancers, lung cancer is the deadliest worldwide, largely because of late diagnoses. Morgan Stanley’s David Lewis and his team write that new tools can disrupt the $6 billion lung biopsy market with better precision and diagnostic accuracy—and that a new system developed via a joint venture between Intuitive Surgical (ISRG) and Fosun International (656.Hong Kong), might be just that tool. Lewis writes that currently, lung biopsy methods have low yields and carry risks, which delays diagnosis and treatment, but that the FC system—a robotic controlled biopsy system using 3D imaging technology to target potential tumors—is more accurate and comes with fewer side effects, which could lower lung cancer mortality.

  • Why $475,000 isn't actually that expensive for Novartis's new drug
    Yahoo Finance2 months ago

    Why $475,000 isn't actually that expensive for Novartis's new drug

    The price tag on Novartis' new cancer drug may be a bargain

  • Trump can lower U.S. drug prices by fixing NAFTA
    Yahoo Finance2 months ago

    Trump can lower U.S. drug prices by fixing NAFTA

    Without intellectual property, there is no innovation—and as we’re rapidly discovering, no customers.

  • Market Realist2 months ago

    What Do Analysts Recommend for Dentsply Sirona?

    Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.

  • Gordon Gekko was right: Stocks are now a zero-sum game
    Yahoo Finance3 months ago

    Gordon Gekko was right: Stocks are now a zero-sum game

    The broad markets have been relatively benign, but trading beneath the surface has been ferocious.

  • Yahoo Finance4 months ago

    Stocks edge up as Q2 draws to a close

    Yahoo Finance's LIVE market market coverage and analysis of stocks and bonds begins each day at 11:45 am ET.

  • Which Medical Funds Generated The Healthiest Returns In May?
    Investor's Business Daily5 months ago

    Which Medical Funds Generated The Healthiest Returns In May?

    Medical related ETFs have racked up healthy gains this year amid the ongoing quest for longer and healthier lives.

  • Investopedia6 months ago

    A Healthy Healthcare ETF

    This was one of 2016's best healthcare ETFs, and the trend is continuing this year.

  • Benzinga10 months ago

    Meet This Year's Best Healthcare ETF

    As has been widely documented, the healthcare sector, the S&P 500's third-largest sector weight, is struggling this year. The Health Care SPDR (ETF) (NYSE: XLV ), the largest healthcare exchange-traded ...

  • Biotech & Pharma ETFs to Suffer in 2017 Too?
    Zacks10 months ago

    Biotech & Pharma ETFs to Suffer in 2017 Too?

    What lies ahead for biotech and pharma ETFs in 2017?